Explaining divergence in catching-up in pharma between India and Brazil using the NSI framework
AbstractSince the mid-twentieth century, the national objective of India and Brazil has been to develop industrial capabilities in essential sectors such as pharmaceuticals. At the outset they shared some common features: a considerable period of lax intellectual property rights regimes, a large internal market and a reasonably strong cadre of scientists and engineers. However, over sixty years, India has had much more success in building indigenous capabilities in pharmaceuticals than Brazil, at least to date. Why? In exploring the answer to this question we show that in both countries the design of State policy played a crucial role and the endogenous responses in the national system of innovation consisted of two parts. On the one hand, most of the time, the predicted and desired outcome was partially realized and on the other hand, there were invariably, other unpredicted responses that emerged. The latter unexpected elements, which were specific to the two countries, pushed them along distinctive trajectories.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic InfoArticle provided by Elsevier in its journal Research Policy.
Volume (Year): 41 (2012)
Issue (Month): 2 ()
Contact details of provider:
Web page: http://www.elsevier.com/locate/respol
Pharmaceutical industry; India; Brazil; Industrial capabilities; Catch-up; National system of innovation;
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- André Nassif, 2007. "National Innovation System And Macroeconomic Policies: Brazil And India In Comparative Perspective," UNCTAD Discussion Papers 184, United Nations Conference on Trade and Development.
- Chittoor, Raveendra & Ray, Sougata & Aulakh, Preet S. & Sarkar, M.B., 2008. "Strategic responses to institutional changes: 'Indigenous growth' model of the Indian pharmaceutical industry," Journal of International Management, Elsevier, vol. 14(3), pages 252-269, September.
- Samira Guennif, 2009. "Aids In India," Working Papers id:1974, eSocialSciences.
- Ryan, Michael P., 2010. "Patent Incentives, Technology Markets, and Public-Private Bio-Medical Innovation Networks in Brazil," World Development, Elsevier, vol. 38(8), pages 1082-1093, August.
- Lee, Keun & Lim, Chaisung, 2001. "Technological regimes, catching-up and leapfrogging: findings from the Korean industries," Research Policy, Elsevier, vol. 30(3), pages 459-483, March.
- Malerba, Franco, 2002. "Sectoral systems of innovation and production," Research Policy, Elsevier, vol. 31(2), pages 247-264, February.
- Ramani, Shyama V., 2002. "Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms," Research Policy, Elsevier, vol. 31(3), pages 381-398, March.
- Athreye, Suma & Kale, Dinar & Ramani, Shyama V., 2008.
"Experimentation with Strategy and the Evolution of Dynamic Capability in the Indian Pharmaceutical Sector,"
MERIT Working Papers
041, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Suma Athreye & Dinar Kale & Shyama V. Ramani, 2009. "Experimentation with strategy and the evolution of dynamic capability in the Indian pharmaceutical sector," Industrial and Corporate Change, Oxford University Press, vol. 18(4), pages 729-759, August.
- Soete, Luc, 1985. "International diffusion of technology, industrial development and technological leapfrogging," World Development, Elsevier, vol. 13(3), pages 409-422, March.
- Gehl Sampath, Padmashree, 2006. "Indian Pharma Within Global Reach?," MERIT Working Papers 031, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Dinar Kale & David Wield, 2008. "Exploitative and Explorative Learning as a Response to the TRIPS Agreement in Indian Pharmaceutical Firms," Industry and Innovation, Taylor & Francis Journals, vol. 15(1), pages 93-114.
- Chadha, Alka, 2009. "TRIPs and patenting activity: Evidence from the Indian pharmaceutical industry," Economic Modelling, Elsevier, vol. 26(2), pages 499-505, March.
- Richard Nelson, 2008.
"Economic Development from the Perspective of Evolutionary Economic Theory,"
Oxford Development Studies,
Taylor & Francis Journals, vol. 36(1), pages 9-21.
- Richard R. Nelson, 2006. "Economic Development from the Perspective of Evolutionary Economic Theory," The Other Canon Foundation and Tallinn University of Technology Working Papers in Technology Governance and Economic Dynamics 02, TUT Ragnar Nurkse School of Innovation and Governance.
- Lall, Sanjaya, 1974. "The International Pharmaceutical Industry and Less-Developed Countries, with Special Reference to India," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 36(3), pages 143-72, August.
- Freeman, Chris, 1995. "The 'National System of Innovation' in Historical Perspective," Cambridge Journal of Economics, Oxford University Press, vol. 19(1), pages 5-24, February.
- Abramovitz, Moses, 1986. "Catching Up, Forging Ahead, and Falling Behind," The Journal of Economic History, Cambridge University Press, vol. 46(02), pages 385-406, June.
- Susan E Feinberg & Sumit K Majumdar, 2001. "Technology Spillovers from Foreign Direct Investment in the Indian Pharmaceutical Industry," Journal of International Business Studies, Palgrave Macmillan, vol. 32(3), pages 421-437, September.
- Chung, Chao-chen, 2013. "Government, policy-making and the development of innovation system: The cases of Taiwanese pharmaceutical biotechnology policies (2000–2008)," Research Policy, Elsevier, vol. 42(5), pages 1053-1071.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Zhang, Lei).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.